Interferon regulatory factor 9 is critical for neointima formation following vascular injury

Nature Communications

Volumn 5, Issue , 2014, Pages

  Zhang, Shu Min ^a,b   Zhu, Li Hua ^a,b   Chen, Hou Zao ^c   Zhang, Ran ^c   Zhang, Peng ^a,b   Jiang, Ding Sheng ^a,b   Gao, Lu ^d   Tian, Song ^b   Wang, Lang ^a,b   Zhang, Yan ^a,b   Wang, Pi Xiao ^a,b   Zhang, Xiao Fei ^b   Zhang, Xiao Dong ^b   Liu, De Pei ^c   Li, Hongliang ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; INTERFERON REGULATORY FACTOR 9; IRF9 PROTEIN, HUMAN; IRF9 PROTEIN, MOUSE; IRF9 PROTEIN, RAT; MMP9 PROTEIN, MOUSE; PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB; SIRT1 PROTEIN, HUMAN; SIRT1 PROTEIN, MOUSE; SIRTUIN 1;

BLOOD; CELLS AND CELL COMPONENTS; GENETIC ANALYSIS; INJURY; MOLECULAR ANALYSIS; PATHOLOGY; PROTEIN; RODENT;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; C57BL MOUSE; CAROTID ARTERY; CELL MIGRATION; CELL MOTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOLOGY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMORAL ARTERY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETIC MANIPULATION; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; MOUSE; NEOINTIMA; NONHUMAN; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; CAROTID ARTERIES; CELL MOVEMENT; CELL PROLIFERATION; CYTOLOGY; FEMORAL ARTERY; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; MALE; MATRIX METALLOPROTEINASE 9; METABOLISM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; PATHOLOGY; PHYSIOPATHOLOGY; PROTO-ONCOGENE PROTEINS C-SIS; RATS; RATS, SPRAGUE-DAWLEY; SIRTUIN 1; VASCULAR SYSTEM INJURIES;

MUS;

EID: 84964305180     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6160     Document Type: Article

References (43)

1. Dzau, V. J., Braun-Dullaeus, R. C. & Sedding, D. G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 8, 1249-1256 (2002).
2. Weintraub, W. S. The pathophysiology and burden of restenosis. Am. J. Cardiol. 100, 3K-9K (2007).
3. Owens, G. K., Kumar, M. S. & Wamhoff, B. R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84, 767-801 (2004).
4. Li, L. et al. SIRT1 acts as a modulator of neointima formation following vascular injury in mice. Circ. Res. 108, 1180-1189 (2011).
5. Ahn, J. D. et al. Inhibitory effects of novel AP-1 decoy oligodeoxynucleotides on vascular smooth muscle cell proliferation in vitro and neointimal formation in vivo. Circ. Res. 90, 1325-1332 (2002).
6. Cho, A. & Reidy, M. A. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ. Res. 91, 845-851 (2002).
7. Ozato, K., Tailor, P. & Kubota, T. The interferon regulatory factor family in host defense: mechanism of action. J. Biol. Chem. 282, 20065-20069 (2007).
8. Tamura, T., Yanai, H., Savitsky, D. & Taniguchi, T. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26, 535-584 (2008).
9. Ikushima, H., Negishi, H. & Taniguchi, T. The IRF family transcription factors at the interface of innate and adaptive immune responses. Cold Spring Harb. Symp. Quant. Biol. 78, 105-116 (2013).
10. Yanai, H., Negishi, H. & Taniguchi, T. The IRF family of transcription factors: inception, impact and implications in oncogenesis. Oncoimmunology 1, 1376-1386 (2012).
11. Maiwald, T. et al. Combining theoretical analysis and experimental data generation reveals IRF9 as a crucial factor for accelerating interferon alpha-induced early antiviral signalling. FEBS. J. 277, 4741-4754 (2010).
12. Takaoka, A. et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424, 516-523 (2003).
13. Luker, K. E., Pica, C. M., Schreiber, R. D. & Piwnica-Worms, D. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res. 61, 6540-6547 (2001).
14. Wang, X. A. et al. Interferon regulatory factor 3 constrains IKKbeta/NF-kappaB signaling to alleviate hepatic steatosis and insulin resistance. Hepatology 59, 870-885 (2014).
15. Wang, X. A. et al. Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 305, E485-E495 (2013).
16. Wang, X. A. et al. Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice. Hepatology 58, 603-616 (2013).
17. Lu, J. et al. Interferon regulatory factor 3 is a negative regulator of pathological cardiac hypertrophy. Basic Res. Cardiol. 108, 326 (2013).
18. Jiang, D. S. et al. Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy. Hypertension 61, 1193-1202 (2013).
19. Jiang, D. S. et al. Interferon regulatory factor 9 protects against cardiac hypertrophy by targeting myocardin. Hypertension 63, 119-127 (2014).
20. Wang, F., Chen, H. Z., Lv, X. & Liu, D. P. SIRT1 as a novel potential treatment target for vascular aging and age-related vascular diseases. Curr. Mol. Med. 13, 155-164 (2013).
21. ER, O. B., Ma, X., Simard, T., Pourdjabbar, A. & Hibbert, B. Pathogenesis of neointima formation following vascular injury. Cardiovasc. Hematol. Disord. Drug Targets 11, 30-39 (2011).
22. Zohlnhofer, D. et al. Transcriptome analysis reveals a role of interferon-gamma in human neointima formation. Mol. Cell 7, 1059-1069 (2001).
23. Michan, S. & Sinclair, D. Sirtuins in mammals: insights into their biological function. Biochem. J. 404, 1-13 (2007).
24. Houtkooper, R. H., Pirinen, E. & Auwerx, J. Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13, 225-238 (2012).
25. Chalkiadaki, A. & Guarente, L. Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat. Rev. Endocrinol. 8, 287-296 (2012).
26. Longo, V. D. & Kennedy, B. K. Sirtuins in aging and age-related disease. Cell 126, 257-268 (2006).
27. Hall, J. A., Dominy, J. E., Lee, Y. & Puigserver, P. The sirtuin family's role in aging and age-associated pathologies. J. Clin. Invest. 123, 973-979 (2013).
28. Mattagajasingh, I. et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA 104, 14855-14860 (2007).
29. Zhang, Q. J. et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc. Res. 80, 191-199 (2008).
30. Zhou, S. et al. Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ. Res. 109, 639-648 (2011).
31. Zhang, R. et al. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J. Biol. Chem. 285, 7097-7110 (2010).
32. Moncada, S. & Higgs, E. A. The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol. 147, S193-S201 (2006).
33. Noriega, L. G. et al. CREB and ChREBP oppositely regulate SIRT1 expression in response to energy availability. EMBO Rep. 12, 1069-1076 (2011).
34. Nemoto, S., Fergusson, M. M. & Finkel, T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306, 2105-2108 (2004).
35. Xiong, S., Salazar, G., Patrushev, N. & Alexander, R. W. FoxO1 mediates an autofeedback loop regulating SIRT1 expression. J. Biol. Chem. 286, 5289-5299 (2011).
36. Hayashida, S. et al. Fasting promotes the expression of SIRT1, an NAD+-dependent protein deacetylase, via activation of PPARalpha in mice. Mol. Cell Biochem. 339, 285-292 (2010).
37. Okazaki, M. et al. PPARbeta/delta regulates the human SIRT1 gene transcription via Sp1. Endocr. J. 57, 403-413 (2010).
38. Zhang, Q. et al. Metabolic regulation of SIRT1 transcription via a HIC1:CtBP corepressor complex. Proc. Natl Acad. Sci. USA 104, 829-833 (2007).
39. Han, L. et al. SIRT1 is regulated by a PPAR{gamma}-SIRT1 negative feedback loop associated with senescence. Nucleic Acids Res. 38, 7458-7471 (2010).
40. Thompson, A. M., Martin, K. A. & Rzucidlo, E. M. Resveratrol induces vascular smooth muscle cell differentiation through stimulation of SirT1 and AMPK. PLoS ONE 9, e85495 (2014).
41. Weihua, X., Lindner, D. J. & Kalvakolanu, D. V. The interferon-inducible murine p48 (ISGF3gamma) gene is regulated by protooncogene c-myc. Proc. Natl Acad. Sci. USA 94, 7227-7232 (1997).
42. Cheng, H.-L. et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl Acad. Sci. USA 100, 10794-10799 (2003).
43. Zhang, S. M. et al. Interferon regulatory factor 8 modulates phenotypic switching of smooth muscle cells by regulating the activity of myocardin. Mol. Cell Biol. 34, 400-414 (2014).